A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
Public ClinicalTrials.gov record NCT02443337. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Study identification
- NCT ID
- NCT02443337
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Interventions
- LY3023414 Drug
- Necitumumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2015
- Primary completion
- Aug 31, 2017
- Completion
- Aug 31, 2017
- Last update posted
- Dec 8, 2020
2015 – 2017
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, P.C. | Mobile | Alabama | 36608 | — |
| Ironwood Cancer & Research Centers | Chandler | Arizona | 85224 | — |
| Comprehensive Cancer Care and Research Institute of Colorado | Englewood | Colorado | 80113 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Palm Beach Cancer Institute | West Palm Beach | Florida | 33401 | — |
| Research Medical Center | Kansas City | Missouri | 64132 | — |
| Oncology Hematology Care Inc. | Cincinnati | Ohio | 45242 | — |
| Chattanooga Oncology Hematology | Chattanooga | Tennessee | 37404 | — |
| SMO Sarah Cannon Research Inst. | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| University of Virginia Health | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02443337, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2020 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02443337 live on ClinicalTrials.gov.